Regeneron Pharmaceuticals, Inc. — Q1 2012 Form 10-Q Summary
Business context and reporting period
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines. This unaudited report covers the three months ended March 31, 2012. The primary commercial development was the November 2011 U.S. launch of EYLEA for wet age-related macular degeneration.
Key financial metrics
| Metric | Q1 2012 | Q1 2011 / Dec. 31, 2011 |
|---|---|---|
| Total revenue | $231.8 million | $112.2 million |
| Net product sales | $127.9 million | $4.4 million |
| EYLEA sales | $123.5 million | Not yet launched |
| ARCALYST sales | $4.4 million | $4.4 million |
| Operating income (loss) | $22.2 million | $(41.0) million |
| Net income (loss) | $11.7 million | $(43.4) million |
| Diluted earnings (loss) per share | $0.11 | $(0.49) |
| Operating margin | Approximately 9.6% | Negative |
| Net margin | Approximately 5.0% | Negative |
| Cash flow from operations | $(87.0) million | $(10.6) million |
| Cash, cash equivalents, and marketable securities | $695.2 million | $810.6 million at Dec. 31, 2011 |
| Convertible senior notes | $280.2 million carrying value | $275.0 million at Dec. 31, 2011 |
Sanofi collaboration revenue was $85.0 million and Bayer HealthCare collaboration revenue was $12.5 million. Research and development expense increased to $138.9 million from $129.4 million, selling, general, and administrative expense increased to $58.4 million from $23.4 million, and cost of goods sold increased to $12.3 million from $0.4 million. Operating expenses included $23.2 million of non-cash stock compensation, compared with $14.8 million in the prior-year quarter.
Total assets were $1.35 billion and stockholders’ equity was $504.0 million at March 31, 2012. Accounts receivable from trade customers increased to $159.5 million from $28.3 million at year-end, principally because of EYLEA sales and extended customer payment terms. One customer represented 80% of net trade receivables. The company had no short-term credit line and reported $4.6 million of letters of credit.
Material changes versus the prior comparable period
- Revenue more than doubled, primarily because EYLEA generated its first full quarter of sales.
- The company moved from a $43.4 million net loss to $11.7 million of net income and from an operating loss to operating income.
- Commercialization drove higher selling and administrative costs, headcount, cost of goods sold, and stock-based compensation.
- Operating cash flow deteriorated to a use of $87.0 million, mainly because Sanofi and trade receivables increased by $135.3 million.
- Cash and marketable securities declined by approximately $115.4 million from December 31, 2011, reflecting operating cash use and financing-related share-tax payments.
- Interest expense increased to $11.2 million from $3.7 million, substantially due to the October 2011 issuance of $400 million of 1.875% convertible senior notes.
- Inventory increased to $20.6 million from $13.6 million, including $1.9 million of inventory write-downs and reserves in Q1 2012.
Guidance, outlook, commentary, risks, and unusual items
Management did not provide conventional full-year revenue or earnings guidance. It stated that profitability and positive operating cash flow over the next several years depend significantly on continued successful commercialization of EYLEA. The company expects substantial ongoing research, development, commercialization, manufacturing, and legal expenditures.
- Management expected approximately $40 million to $60 million of capital expenditures during the remainder of 2012, primarily for Tarrytown facilities, Rensselaer manufacturing capacity, and equipment.
- For 2012 funding requirements, management estimated that 40% to 50% would support technology development, basic research, and early preclinical and clinical activities; 15% to 20% commercialization of new indications and ZALTRAP; and 15% to 20% capital expenditures.
- Key pending regulatory events included FDA decisions for ZALTRAP in metastatic colorectal cancer by August 4, 2012, EYLEA in central retinal vein occlusion by September 23, 2012, and ARCALYST for gout flares by July 30, 2012.
- ZALTRAP’s Phase 3 VELOUR trial was positive in previously treated metastatic colorectal cancer, but the Phase 3 VENICE prostate cancer trial did not meet its overall-survival criterion.
- REGN475 remained on FDA clinical hold because of class-related anti-NGF safety concerns; Sanofi elected not to continue co-development, although Sanofi remained obligated to fund agreed costs through 2012.
- The Genentech settlement provides a U.S. license for EYLEA eye indications but requires a $60 million payment when cumulative U.S. EYLEA sales reach $400 million, plus royalties of 4.75% on cumulative sales from $400 million to $3 billion and 5.5% above $3 billion through May 2016.
- Remaining Genentech litigation covers matters outside the settlement, including non-U.S. disputes and activities relating to VEGF Trap other than covered U.S. EYLEA uses. The company could not estimate the probability or amount of any loss.
- EYLEA faces competition from Lucentis and lower-cost off-label Avastin, as well as reimbursement, pricing, manufacturing, supply, regulatory, safety, and market-acceptance risks.
- Sanofi and Bayer collaborations provide significant funding and operational support. Termination or reduced funding could materially increase Regeneron’s funding requirements.
- The company continued to maintain a full valuation allowance against deferred tax assets because of its history of losses; no substantive federal or state cash tax obligations were expected over the next several years.
Most important facts for investors to verify
- Whether EYLEA sales growth, customer collections, and reimbursement support continue sufficiently to offset commercialization and research spending.
- The timing and outcomes of the pending FDA decisions for ZALTRAP, EYLEA in additional indications, and ARCALYST for gout flares.
- Cash conversion and working-capital trends, particularly the large increase in trade receivables and the continued use of operating cash.
- The economic impact of convertible debt, potential dilution, lease obligations, and the Genentech payment and royalty obligations.
- The status and potential exposure from Genentech patent litigation, including the adverse United Kingdom decision under appeal.
- Clinical safety, efficacy, manufacturing capacity, and competitive positioning of EYLEA and the broader development pipeline.
- Continuity and funding terms of the Sanofi and Bayer collaborations, including potential reimbursement obligations if the collaborations become profitable.